Eli Lilly and Co.

21. Sept. 2026, 23:11 UTC

Eli Lilly has started construction on a $6.5 billion facility in Houston to produce its GLP-1 receptor agonist, Foundayo, creating over 600 permanent jobs.

16. Sept. 2026, 20:10 UTC

Ginkgo Bioworks partners with Eli Lilly's TuneLab to enhance biotech innovation, while Twist Bioscience provides antibody data services; shares are slightly higher.

15. Sept. 2026, 23:01 UTC

Eli Lilly shares are trading roughly flat after-market with no specific news. Broader market sentiment is impacted by a decline in the Empire State Manufacturing Index.

14. Sept. 2026, 23:06 UTC

Eli Lilly's Foundayo captures over 30% of new U.S. obesity patients, boosting shares higher in after-market hours amid strong demand for oral treatments.

10. Sept. 2026, 20:07 UTC

Eli Lilly shares are lower as HSBC maintains a Reduce rating and raises the price target to $940 amid ongoing challenges and sector decline.

9. Sept. 2026, 19:16 UTC

Eli Lilly received FDA approval for Mounjaro, enhancing its growth potential. Analysts maintain a favorable outlook as shares advance during Wednesday's session.

8. Sept. 2026, 23:06 UTC

Eli Lilly's Mounjaro received FDA approval to reduce heart-attack and stroke risk in adults with type 2 diabetes. Shares advanced slightly in after-market trading.

2. Sept. 2026, 19:46 UTC

Eli Lilly shares are higher since Tuesday, despite earlier pulling back from an intraday peak. The stock remains below its 20-day moving average.

1. Sept. 2026, 20:09 UTC

Eli Lilly gains as it announces acquisition of Merida Biosciences for up to $2.875 billion and prepares for the Morgan Stanley Healthcare Conference.

31. Aug. 2026, 23:06 UTC

Eli Lilly shares are higher in after-market trading following regulatory clearance for its merger with AtaiBeckley, marking a key milestone in the process.

28. Aug. 2026, 23:01 UTC

Eli Lilly's shares rise in after-market trading following FDA approval of Mounjaro for reducing cardiovascular risks in type 2 diabetes patients.

27. Aug. 2026, 23:02 UTC

Eli Lilly and Co shares are lower in after-market hours, continuing a trend of five consecutive sessions with lower closes. No specific news was identified.

26. Aug. 2026, 20:08 UTC

Eli Lilly shares are lower today, retreating from recent record highs. Positive data on weight-loss drug Zepbound indicates significant healthcare cost savings for patients.

25. Aug. 2026, 23:06 UTC

Eli Lilly shares are lower in after-market hours, continuing a three-day decline. Broader market sentiment is impacted by a significant drop in crude oil prices.

24. Aug. 2026, 23:01 UTC

Eli Lilly shares are lower in after-market hours, with no specific news cited. Geopolitical tensions may be influencing broader market sentiment.

21. Aug. 2026, 23:16 UTC

Eli Lilly and Co shares are higher in after-market trading, remaining near the upper end of their one-month range and above the 20-day moving average.

20. Aug. 2026, 23:01 UTC

Eli Lilly shares are lower in after-market hours, following broader U.S. stock weakness amid concerns over consumer spending and inflation pressures.

19. Aug. 2026, 23:02 UTC

Eli Lilly shares declined in after-market hours, reflecting concerns over investment concentration in its GLP-1 franchise amid ongoing social media discussions.

18. Aug. 2026, 23:06 UTC

Eli Lilly shares are lower in after-market hours amid scrutiny over its planned acquisition of Sangamo's gene therapy technologies from Genentech and others.

17. Aug. 2026, 23:06 UTC

Eli Lilly and Co. shares showed little change in after-market trading, remaining within a narrow range since Monday's close.

14. Aug. 2026, 20:02 UTC

Eli Lilly shares are lower as analysts raise concerns after a revenue miss and lower adjusted EPS guidance, despite U.K. approval for its weight loss drug.

13. Aug. 2026, 19:36 UTC

Eli Lilly shares are lower as Investor Business Daily's SwingTrader sells its position, raising concerns about investor sentiment and pricing strategy for GLP-1 medications.

12. Aug. 2026, 23:01 UTC

Eli Lilly filed six lawsuits against U.S. companies over unauthorized sales of its obesity drug retatrutide. Shares are lower in after-market trading.

11. Aug. 2026, 19:36 UTC

Eli Lilly's stock is declining despite UK approval of its GLP-1 pill for diabetes and weight management, amid cautious investor sentiment following recent gains.

10. Aug. 2026, 23:16 UTC

Eli Lilly and Co shares are lower in after-market hours, following a narrow trading range since Monday's close and reflecting broader market trends.

8. Aug. 2026, 00:02 UTC

Eli Lilly shares are higher in after-market trading following FDA filing plans for retatrutide, a potential competitor in the weight-loss market.

7. Aug. 2026, 19:16 UTC

Eli Lilly shares are lower today, despite an increase in TRx sales to 34,219 from 29,388 last week. The stock remains within its one-month range.

6. Aug. 2026, 19:16 UTC

Eli Lilly shares rose as analysts raised price targets, reflecting strong quarterly results and demand growth for its obesity drugs.

5. Aug. 2026, 23:42 UTC

Eli Lilly reported second-quarter revenue of $23 billion, raising its full-year guidance to $85 billion to $87 billion. Shares are higher in after-market trading.

4. Aug. 2026, 23:02 UTC

Eli Lilly shares are higher in after-market trading, driven by a broader market rally and optimism surrounding potential oil supply agreements.